Loading…
← CockpitCompetitor Analysis › 600285.SS Henan Lingrui Pharmaceutial Co., Ltd. Class AOpen in the cockpit ↗

Henan Lingrui Pharmaceutial Co., Ltd. Class A600285.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Henan maker of transdermal medicated patches for joint and muscle pain, a leading Chinese OTC patch brand.

≈ A Chinese Salonpas / Icy Hot makerMomentum leader 98
Mkt cap
$2.04B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$47.7M
20-day average traded
Fwd P/E
15.9×
forward earnings
ROIC−WACC
+20.4 pp
WACC 5.0%
Hurdle
-15 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥24.11
1D+0.5%
1W+7.0%
1M+13.8%
3M+22.6%
6M+9.3%
YTD+16.4%
1Y+8.5%
ATR %3.0%
52w lowhigh1.4% off high

What Henan Lingrui Pharmaceutial does

Henan maker of transdermal medicated patches for joint and muscle pain, a leading Chinese OTC patch brand.

In one line: A Chinese Salonpas / Icy Hot maker.

Products and services

  • Medicated pain-relief patches
  • Other TCM and OTC products

Customers

  • Retail pharmacies
  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • OTC/consumer health
  • Topical pain-relief patches

What could go right

  • Aging population and joint-pain treatment demand
  • OTC channel expansion

What could go wrong

  • OTC price competition
  • Raw-material cost swings

Moat: narrow (brand, distribution). Long-established OTC patch brand with wide pharmacy shelf presence across China.

Headquarters: Xinyang, Henan, China · Employees: 2,789

Named competitors

Henan Lingrui Pharmaceutial at a glance

Size Henan Lingrui Pharmaceutial (600285.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.04B, the 1147th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.11 on 18 Nov 2026.

Performance Over six months the shares gained 9.3%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +11.1%); the operating margin is 22.4% (peer median 16.6%).

Valuation It trades at 15.9× forward earnings against a peer median of 23.8× (7th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 20.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026600285.SS 111Peer median 97
Six months, rebased to 100: Henan Lingrui Pharmaceutial against the median of its 20 peers (local-currency closes).

Henan Lingrui Pharmaceutial financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.95BCN¥3.81BCN¥3.46BCN¥3.28BCN¥2.97B
Revenue growth—+10%+5%+10%—
Gross profitCN¥3.15BCN¥3.01BCN¥2.58BCN¥2.36BCN¥2.11B
EBITDAn/aCN¥923MCN¥799MCN¥670MCN¥466M
Net incomeCN¥827MCN¥760MCN¥723MCN¥568MCN¥465M
Free cash flowCN¥1.08BCN¥531MCN¥781MCN¥806MCN¥822M
Capital expenditureCN¥59.7MCN¥56.8MCN¥115MCN¥21.2MCN¥27.0M
Total debtCN¥322MCN¥437MCN¥133MCN¥256MCN¥224M

Quarterly statements and history in the cockpit →

Henan Lingrui Pharmaceutial competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%603707603456300436688428009420H02ERIS214450BHVNONESOURCEHRMY60020145400512SHILPAMEDALIVUS600267600867APLLTDPFIZER600285.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Henan Lingrui Pharmaceutial is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×603707603456688428H02ERIS214450ONESOURCEHRMY6002014540SHILPAMED600267600285.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Henan Lingrui Pharmaceutial is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%603707603456688428ERIS214450600267600285.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Henan Lingrui Pharmaceutial is the large dot.

Henan Lingrui Pharmaceutial competitors and peer comparison

Head to head with its named competitors (600285.SS vs 603858.SS vs 600422.SS vs 600329.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Henan Lingrui Pharmaceutial 600285.SS$2.04B+9%+5%22%15.9×-4.7%
Shandong Buchang Pharmaceuticals 603858.SS$2.25B-7%+4%10%n/a-2.5%
KPC Pharmaceuticals 600422.SS$940M-6%-41%-10%n/an/a
Tianjin Pharmaceutical Da Ren Tang 600329.SS$3.75B-10%-13%20%28.5×16.2%

How Henan Lingrui Pharmaceutial compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Henan Lingrui Pharmaceutial against its 20 peers (data as of 18 Nov 2026)
Measure600285.SSPeer medianRank in peer set
1-month return+13.8%+0.2%6th highest of 21
6-month return+9.3%-1.3%8th highest of 21
Distance from 52-week high-1.4%-28.2%highest of 21
Revenue growth (TTM)+4.7%+11.1%5th lowest of 20
Operating margin22.4%16.6%7th highest of 19
Forward P/E15.9×23.8×7th cheapest of 18
Growth the price implies (Req g, 7 yrs)-4.7%2.5%5th least demanding of 15
Growth delivered (Del g)+10.6%+10.3%8th highest of 15
Hurdle (Req g minus delivered)-15.2 pp-4.7 pp4th least demanding of 15
ROIC minus cost of capital+20.4 pp-0.5 pp4th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%

Questions

Who are Henan Lingrui Pharmaceutial's main competitors?
Named competitors: Buchang Pharmaceutical (603858.SS), Kunming Pharmaceutical (600422.SS), Tianjin Zhongxin Pharmaceutical (600329.SS). The cockpit's measured peer set (industry) also includes Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Fujian Cosunter Pharmaceutical (300436.SZ), InnoCare Pharma (688428.SS), Hanall Biopharma (009420.KS), Haw Par (H02.SI).
Is Henan Lingrui Pharmaceutial expensive compared with its peers?
On forward p/e it trades at 15.9× against a peer median of 23.8×, 7th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Henan Lingrui Pharmaceutial stock performed?
Over six months to 18 Nov 2026 the shares returned +9.3% against -1.3% for the median peer; over one year +8.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.